Literature DB >> 32152628

Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.

Srivandana Akshintala1, Andrea Baldwin1, David J Liewehr2, Anne Goodwin1, Jaishri O Blakeley3, Andrea M Gross1, Seth M Steinberg2, Eva Dombi1, Brigitte C Widemann1.   

Abstract

BACKGROUND: Understanding the natural history of non-malignant peripheral nerve sheath tumors (PNSTs) in neurofibromatosis type 1 (NF1) is critical to optimal clinical care and the development of meaningful clinical trials.
METHODS: We longitudinally analyzed growth of plexiform neurofibromas (PNs) and of PNSTs with distinct nodular appearance (distinct nodular lesions [DNLs]) using volumetric MRI analysis in patients enrolled on a natural history study (NCT00924196).
RESULTS: DNLs were observed in 58/122 (45.6%) patients (median 2 DNLs/patient). In DNLs that developed during follow-up, median age of development was 17 years. A moderate negative correlation was observed between the estimated PN growth rate and patients' age at initial MRI (Spearman's r [95% CI]: -0.60 [-0.73, -0.43], n = 70), whereas only a weak correlation was observed for DNLs (Spearman's r [95% CI]: -0.25 [-0.47, 0.004]; n = 61). We observed a moderate negative correlation between tumor growth rate and baseline tumor volume for PNs and DNLs (Spearman's r [95% CI]: -0.52 [-0.67, -0.32] and -0.61 [-0.75, -0.42], respectively). Spontaneous tumor volume reduction was observed in 10 PNs and 7 DNLs (median decrease per year, 3.6% and 7.3%, respectively).
CONCLUSION: We corroborate previously described findings that most rapidly growing PNs are observed in young children. DNLs tend to develop later in life and their growth is minimally age related. Distinct growth characteristics of PNs and DNLs suggest that these lesions have a different biology and may require different clinical management and clinical trial design. In a subset of PNs and DNLs, slow spontaneous regression in tumor volume was seen. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2020.

Entities:  

Keywords:  atypical neurofibroma; neurofibromatosis; plexiform neurofibroma; volumetric MRI

Mesh:

Year:  2020        PMID: 32152628      PMCID: PMC7523449          DOI: 10.1093/neuonc/noaa053

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  24 in total

1.  The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.

Authors:  Christine S Higham; Eva Dombi; Aljosja Rogiers; Sucharita Bhaumik; Steven Pans; Steve E J Connor; Markku Miettinen; Raf Sciot; Roberto Tirabosco; Hilde Brems; Andrea Baldwin; Eric Legius; Brigitte C Widemann; Rosalie E Ferner
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

2.  Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits.

Authors:  Rosa Nguyen; Lan Kluwe; Carsten Fuensterer; Michael Kentsch; Reinhard Edgar Friedrich; Victor-Felix Mautner
Journal:  J Pediatr       Date:  2011-05-31       Impact factor: 4.406

3.  Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.

Authors:  Elina Uusitalo; Matti Rantanen; Roope A Kallionpää; Minna Pöyhönen; Jussi Leppävirta; Heli Ylä-Outinen; Vincent M Riccardi; Eero Pukkala; Janne Pitkäniemi; Sirkku Peltonen; Juha Peltonen
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

4.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Authors:  Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

5.  NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

Authors:  E Dombi; J Solomon; A J Gillespie; E Fox; F M Balis; N Patronas; B R Korf; D Babovic-Vuksanovic; R J Packer; J Belasco; S Goldman; R Jakacki; M Kieran; S M Steinberg; B C Widemann
Journal:  Neurology       Date:  2007-01-10       Impact factor: 9.910

Review 6.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Authors:  Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry
Journal:  Hum Pathol       Date:  2017-05-24       Impact factor: 3.466

7.  Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.

Authors:  Carlos E Prada; Fatima A Rangwala; Lisa J Martin; Anne M Lovell; Howard M Saal; Elizabeth K Schorry; Robert J Hopkin
Journal:  J Pediatr       Date:  2011-10-11       Impact factor: 4.406

8.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

9.  Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.

Authors:  A Kim; A Gillespie; E Dombi; A Goodwin; W Goodspeed; E Fox; F M Balis; B C Widemann
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

10.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Authors:  Victor-F Mautner; Florence A Asuagbor; Eva Dombi; Carsten Fünsterer; Lan Kluwe; Ralf Wenzel; Brigitte C Widemann; Jan M Friedman
Journal:  Neuro Oncol       Date:  2008-06-17       Impact factor: 12.300

View more
  8 in total

1.  Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1.

Authors:  Helen Toledano; Gad Dotan; Rivka Friedland; Rony Cohen; Iftach Yassur; Hagit Toledano-Alhadef; Shlomi Constantini; Mika Shapira Rootman
Journal:  Childs Nerv Syst       Date:  2021-03-22       Impact factor: 1.475

Review 2.  Brain Cancers in Genetic Syndromes.

Authors:  Edina Komlodi-Pasztor; Jaishri O Blakeley
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-22       Impact factor: 5.081

3.  Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth.

Authors:  Lennart Well; Kimberly Döbel; Lan Kluwe; Peter Bannas; Said Farschtschi; Gerhard Adam; Victor-Felix Mautner; Johannes Salamon
Journal:  PLoS Genet       Date:  2021-05-05       Impact factor: 5.917

4.  The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors.

Authors:  Ignazio G Vetrano; Michele Dei Cas; Vittoria Nazzi; Marica Eoli; Niccolò Innocenti; Veronica Saletti; Antonella Potenza; Tatiana Carrozzini; Giuliana Pollaci; Gemma Gorla; Rita Paroni; Riccardo Ghidoni; Laura Gatti
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

5.  Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1.

Authors:  Caitlin Tydings; Pavel Yarmolenko; Miriam Bornhorst; Eva Dombi; John Myseros; Robert Keating; James Bost; Karun Sharma; AeRang Kim
Journal:  Neurooncol Adv       Date:  2021-08-18

6.  Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.

Authors:  Jeffrey J Szymanski; R Taylor Sundby; Paul A Jones; Divya Srihari; Noah Earland; Peter K Harris; Wenjia Feng; Faridi Qaium; Haiyan Lei; David Roberts; Michele Landeau; Jamie Bell; Yi Huang; Leah Hoffman; Melissa Spencer; Matthew B Spraker; Li Ding; Brigitte C Widemann; Jack F Shern; Angela C Hirbe; Aadel A Chaudhuri
Journal:  PLoS Med       Date:  2021-08-31       Impact factor: 11.069

7.  Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.

Authors:  Austin K Mattox; Christopher Douville; Natalie Silliman; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Maria Popoli; Cherie Blair; Kathy Judge; Kai Pollard; Christine Pratilas; Jaishri Blakeley; Fausto Rodriguez; Nickolas Papadopoulos; Allan Belzberg; Chetan Bettegowda
Journal:  Elife       Date:  2022-03-04       Impact factor: 8.713

8.  Surgical Treatment and Complications of Deep-Seated Nodular Plexiform Neurofibromas Associated with Neurofibromatosis Type 1.

Authors:  Kunihiro Ikuta; Yoshihiro Nishida; Tomohisa Sakai; Hiroshi Koike; Kan Ito; Hiroshi Urakawa; Shiro Imagama
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.